ADRA2B encodes the α2B-adrenergic receptor, a G protein-coupled receptor that binds catecholamines and activates inhibitory G(i/o) signaling, suppressing adenylyl cyclase activity and reducing calcium channel conductance. It regulates blood pressure, lipolysis, and insulin release. A common 3-bp deletion variant in ADRA2B shows markedly reduced receptor desensitization in vitro, though it does not substantially alter vascular sensitivity to selective agonists like dexmedetomidine in vivo 1. The deletion variant is associated with enhanced perceptual and cognitive processing of emotional information across a meta-analysis of 2,752 participants, with stronger coupling between subjective emotional arousal at encoding and subsequent emotional memory retrieval [PMID:29751052; 28]. Recent evidence suggests ADRA2B activation by adrenaline can suppress caspase-11-dependent inflammasome activation and pyroptosis during sepsis through cAMP-dependent protein kinase A signaling 3. Approved α2-adrenergic agonists and antagonists targeting this receptor include clonidine, brimonidine, dexmedetomidine, and yohimbine, which are used clinically for glaucoma, hypertension, anesthesia, and other conditions. ADRA2B polymorphisms have been studied in migraine and cardiovascular disease, though associations remain inconsistent across populations [PMID:20651814; 47].